• Publications
  • Influence
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available. TheExpand
  • 1,638
  • 117
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
N 1988, THE National Cancer Institute-sponsored Working Group (NCI-WC) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials in CLL with two majorExpand
  • 1,924
  • 91
  • PDF
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, aExpand
  • 2,778
  • 60
  • PDF
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
BACKGROUND The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV(H)) andExpand
  • 929
  • 52
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
This study investigated the efficacy, safety, and clinical benefit of alemtuzumab (Campath-1H) for patients with relapsed or refractory B-cell chronic lymphocytic leukemia exposed to alkylatingExpand
  • 969
  • 45
  • PDF
Chronic lymphocytic leukemia.
From the Institute for Medical Research, North Shore–LIJ Health System (N.C., K.R.R.), and the Departments of Medicine, North Shore University Hospital, Manhasset, N.Y., and New York UniversityExpand
  • 1,103
  • 43
  • PDF
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
BACKGROUND Fludarabine is an effective treatment for chronic lymphocytic leukemia that does not respond to initial treatment with chlorambucil. We compared the efficacy of fludarabine with that ofExpand
  • 1,027
  • 39
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
We examined isolated leukemia B cells of patients with chronic lymphocytic leukemia (CLL) for expression of zeta-associated protein 70 (ZAP-70). CLL B cells that have nonmutated immunoglobulinExpand
  • 532
  • 25
  • PDF
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Cellular immunophenotypic studies were performed on a cohort of randomly selected IgM + B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V H and V L gene sequences were available. The casesExpand
  • 1,104
  • 22
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
PURPOSE This phase II pilot study determined the efficacy and safety of alemtuzumab (Campath-1H; Burroughs Wellcome, United Kingdom) in patients with chronic lymphocytic leukemia (CLL), all of whomExpand
  • 323
  • 16